Advertisement

Search Results

Advertisement



Your search for Keith T. Flaherty, MD,Keith T. Flaherty, MD matches 18 pages

Showing 1 - 18


AACR Announces Fellows of the AACR Academy Class of 2023

The American Association for Cancer Research (AACR) recently announced its newly elected class of Fellows of the AACR Academy. Fellows of the AACR Academy serve as a global brain trust of top contributors to cancer science and medicine who help advance the mission of the AACR to prevent and cure...

skin cancer
immunotherapy
genomics/genetics

Keith T. Flaherty, MD, on Results From the DREAMseq Trial

Invited discussant of the phase III DREAMseq trial, Keith T. Flaherty, MD, said the findings still leave room for nuanced decision-making.1 Dr. Flaherty is Professor of Medicine at Harvard and Director of the Henri and Belinda Termeer Center for Targeted Therapy at the Massachusetts General...

genomics/genetics

Molecular Profiles and Actionable Alterations Identified in the NCI-MATCH Trial

In a report in the Journal of Clinical Oncology, Keith T. Flaherty, MD, and colleagues describe the current status of and findings from the ongoing NCI-MATCH (National Cancer Institute Molecular Analysis for Therapy Choice) trial. The aim of the trial is to determine the likelihood of identifying...

2020 Class of Giants of Cancer Care Announced

The Eighth Annual Giants of Cancer Care class of inductees was recently announced by OncLive, a multimedia resource focused on providing oncology professionals with relevant information on patient care. The virtual awards ceremony will be held on November 5 at 7.30 PM EST and will be available...

covid-19

Repurposing Drugs for the Treatment of COVID-19

A vaccine for COVID-19 is currently the Holy Grail, but even if an effective vaccine were developed on a fast-track timetable, it may be effective in only a percentage of people, judging by existing flu vaccines, which show efficacy rates of approximately 45% and vary year by year. Until we have a...

head and neck cancer

T-DM1 Shows Activity in HER2-Amplified Salivary Gland Cancer in Small Patient Sample of NCI-MATCH

The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) showed activity in HER2-amplified salivary gland tumors, according to data published by Jhaveri et al in Annals of Oncology. The publication is for ‘Arm Q,’ which is one of nearly 40 single-arm phase II treatments in the NCI-Molecular...

symptom management
immunotherapy

Both Patients and Clinicians Face Challenges in Recognizing and Reporting Immune-Related Adverse Events

The publication of ASCO’s toxicity management guidelines for immune checkpoint antibodies by Brahmer and colleagues,1 reviewed in this issue of The ASCO Post, has been long awaited, considering more than 15 distinct indications have been granted by the U.S. Food and Drug Administration (FDA). The ...

Keith T. Flaherty, MD, Named New Editor-in-Chief of Clinical Cancer Research

The American Association for Cancer Research (AACR) recently announced the appointment of Keith T. Flaherty, MD, as Editor-in-Chief of Clinical Cancer Research. Dr. Flaherty is Director of the Termeer Center for Targeted Therapies and Director of Clinical Research at the Massachusetts General...

issues in oncology
genomics/genetics

Psychological Impact of Genetic Testing to Be Explored in Subset of NCI-MATCH Trial Patients

The Eastern Cooperative Oncology Group–American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group has received federal approval to add a quality-of-life research study, Communication and Education in Tumor Profiling (EAQ152), or COMET, to the NCI-MATCH (EAY131) trial, which is ...

issues in oncology

Psychological Impact of Genetic Testing to Be Explored in Subset of NCI-MATCH Trial Patients

The ECOG-ACRIN Cancer Research Group has received federal approval to add a quality-of-life research study, COMmunication and Education in Tumor Profiling, or COMET (EAQ152), to the NCI-MATCH (EAY131) trial already underway. Using feedback surveys before and after a patient undergoes tumor gene...

SIDEBAR: Expect Questions from Your Patients

Promising results announced at the recent ASCO Annual Meeting from studies with BRAF and MEK inhibitors have made headlines, but only one of these agents—the BRAF inhibitor vemurafenib (Zelboraf)—has been approved by the FDA. The others are still investigational. Patients interested in gaining...

skin cancer

MEK Inhibitor Reduces Progression of BRAF-mutated Melanoma and Might also Benefit Others

In the News focuses on media reports that your patients may have questions about at their next visit. This continuing column will provide summaries of articles in the popular press that may prompt such questions, as well as comments from colleagues in the field. The MEK inhibitor trametinib...

Combination Therapy Not Better than Single-agent Bevacizumab for Advanced Renal Cell Carcinoma in BeST Trial

None of three combination therapies tested among patients with advanced renal cell carcinoma in the BeST trial came close to achieving the primary objective of a 67% improvement in median progression-free survival compared to single-agent bevacizumab (Avastin), Keith T. Flaherty, MD, reported at...

skin cancer

BRAF/MEK Inhibition in BRAF-Mutant Advanced Melanoma

Preliminary evidence of efficacy for BRAF inhibitors as monotherapy in advanced melanoma first emerged in 2009.1 Phase II and III trials rapidly ensued for vemurafenib (Zelboraf) and dabrafenib (Tafinlar), leading to U.S. Food and Drug Administration (FDA) approval in 2011. As a result of melanoma...

Expert Point of View: Keith T. Flaherty, MD

Keith T. Flaherty, MD, Associate Professor of Medicine, Harvard Medical School, and Director of the Termeer Center for Targeted Therapy, Boston, was interviewed by The ASCO Post for his thoughts on the findings from Atreya and colleagues. He believes the study’s outcomes are sufficient for...

kidney cancer
kidney cancer

Phase II Trial Indicates No Benefit of Sorafenib, Temsirolimus, or Bevacizumab Doublets vs Bevacizumab Alone in Advanced Renal Cell Carcinoma

In a randomized phase II trial (BEST; ECOG-ACRIN E2804) reported in the Journal of Clinical Oncology, Flaherty et al found that adding the VEGFR inhibitor sorafenib (Nexavar) or the mTOR inhibitor temsirolimus (Torisel) to the VEGF inhibitor bevacizumab (Avastin) or using sorafenib-temsirolimus in...

issues in oncology

ASCO 2015: NCI-MATCH Trial Links Targeted Drugs to Genetic Abnormalities

Investigators for the nationwide trial NCI-MATCH: Molecular Analysis for Therapy Choice announced at the 2015 ASCO Annual Meeting in Chicago that the precision medicine trial will open to patient enrollment in July. The trial seeks to determine whether targeted therapies for people whose tumors...

skin cancer

Progression-Free Survival Can Be Used as Surrogate for Overall Survival in Metastatic Melanoma Trials With Dacarbazine Control Group

In a meta-analysis reported in The Lancet Oncology, Flaherty et al found that progression-free survival is a reliable surrogate for overall survival in clinical trials in metastatic melanoma that include dacarbazine as control treatment. Study Details In the analysis, 1,649 reports and meeting...

Advertisement

Advertisement




Advertisement